SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Phase 0 Completed 28 enrolled Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of SHR0302 in combination with Prednisone as first line therapy in patients with moderate to severe chronic graft-versus-host disease (GVHD).

Timeline

Start: 2020-04-02
Primary completion: 2024-09-30
Completion: 2024-10-31

Publications

He Q, Sun X, Niu J, Yang J, Wang Y, Huang C, Zhou K, Tong Y, Cai Y, Dong B, Wan L, Song X, Qiu H. A Novel JAK1 Inhibitor SHR0302 Combined With Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease: A Phase I Clinical Trial. Cell Transplant. 2024 Jan-Dec;33:9636897241254678. doi: 10.1177/09636897241254678.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR0302	Unknown	—	Oral
Background	Prednisone	Other / unclassified	1 mg/kg	Oral

SHR0302 and Steroid As First Line Therapy for Chronic GVHD

Summary

Timeline

Publications

Drugs

Indications